Forecast horizon — calibration-scored at resolution.
By 2028, oral CGRP antagonists will be first-line preventive therapy for episodic migraine, surpassing beta-blockers in new prescriptions.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1728
The ADVANCE (atogepant) trial's stated primary conclusion — Atogepant, an oral CGRP receptor antagonist, reduces monthly migraine days in episodic migraine preventive therapy. — replicates in independent cohorts.
0.2117
By 2028, ARNI will remain preferred over ACEi as baseline RAS modulation in HFrEF across US and EU guidelines.
0.2285
Recent follow-up analyses of ADVANCE (atogepant) are confirming the original effect size in real-world data.
0.2362
By 2028, flow-diverter use will extend to posterior circulation aneurysms with safety non-inferior to anterior-circulation benchmarks.
0.2443
By 2028, SGLT2 inhibitors will be prescribed for ≥70% of eligible HFrEF patients at guideline-adherent cardiology practices.
0.2455
By 2028, quadruple therapy (ACEi/ARNI + BB + MRA + SGLT2i) will be the default HFrEF regimen in US registries.